Personalized mRNA vaccine after lung cancer surgery
Treatments studied
Part of Cancer clinical trials.
This trial tests a personalized mRNA vaccine made from your tumor's unique mutations. It's given after surgery to help your immune system fight any remaining cancer cells and prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have had surgery to remove your non-small cell lung cancer and have enough tumor tissue for testing.
- Your tumor must not have EGFR or ALK gene mutations.
- You should be in good physical condition (able to do daily activities without help).
- You must not have an active autoimmune disease or serious infection.
- You must agree to use effective birth control during and for 90 days after the trial.
- You need to have no other cancers in the past 5 years, except for some very early-stage or cured ones.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized mRNA vaccine (made from your tumor's unique markers) combined with the immunotherapy drug adebrelimab for people with non-small cell lung cancer. It may help your immune system fight cancer cells that remain after standard treatment.
This trial tests a combination of radiation, immunotherapy (QL1706), and chemotherapy given before surgery for non-small-cell lung cancer that can be removed. It aims to see if this approach can shrink the tumor and improve outcomes.
This trial tests a personalized mRNA vaccine made from your tumor's unique markers (neoantigens) to train your immune system to fight cancer. It is for people with advanced solid tumors who have not had gene therapy and are healthy enough for the vaccine.
This trial tests a personalized mRNA cancer vaccine (RH125) for people with advanced solid tumors that have spread or cannot be removed by surgery. It may be an option if standard treatments have stopped working or are not suitable, and for some, it will be given with a PD-1 blocker.
This study tests a combination of a personalized vaccine made from your tumor's unique markers, a type of immunotherapy (PD-1 inhibitor), and radiation. The goal is to see if this mix can work better for advanced lung cancer that has progressed after initial treatment.
This trial tests a combination of a personalized vaccine (made from your tumor's unique markers), a drug that boosts your immune system (PD-1 inhibitor), and targeted radiation for people with advanced lung cancer that has progressed after initial treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.